Mezgebe Berhe, MD
Infectious Disease · Dallas, TXNPI 1831155787
Payments from drug & device makers
Across 1,356 payments — averaging $8075.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$4.1M
- Regeneron$2.4M
- Gilead$1.3M
- Biontech SE$880K
- Viiv Healthcare Company$733K
- Karyopharm Therapeutics Inc.$591K
- plus $899K from 31 others
Across 17 payments — averaging $273.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$3K
- Gilead$1K
- Viiv Healthcare Company$415
What the payments were for
- Consulting fees$42,66564%
- Speaking & faculty fees$4,2756%
- Travel & lodging$3,6946%
- Food & beverage$15,51723%
- Education$3150%
- Gifts$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 186 | $4,141,896 |
| Regeneron | 80 | $2,370,541 |
| Gilead | 277 | $1,334,460 |
| Biontech SE | 82 | $880,049 |
| Viiv Healthcare Company | 308 | $732,887 |
| Karyopharm Therapeutics Inc. | 18 | $591,169 |
| Janssen Research & Development, LLC | 97 | $393,636 |
| Theratechnologies Inc. | 19 | $280,341 |
| GSK | 18 | $178,393 |
| Mannkind Corporation | 4 | $20,377 |
| Rebiotix Inc. | 2 | $10,313 |
| Insmed, Inc. | 54 | $7,694 |
| Ferring Pharmaceuticals AS | 3 | $4,550 |
| Merck | 45 | $849 |
| Shionogi Inc | 39 | $663 |
| AbbVie(2 entities) | 27 | $513 |
| Astellas Pharma US Inc | 22 | $483 |
| Johnson & Johnson | 28 | $431 |
| Janssen Products, LP | 1 | $125 |
| Mayne Pharma Commercial LLC | 7 | $124 |
| EMD Serono, Inc. | 5 | $92 |
| Grifols USA, LLC | 4 | $89 |
| Paratek Pharmaceuticals, Inc. | 6 | $88 |
| Ferring Pharmaceuticals Inc. | 3 | $76 |
| Hospira, Inc. | 4 | $69 |
| Amgen | 3 | $60 |
| Napo Pharmaceuticals Inc | 2 | $40 |
| Aimmune Therapeutics, Inc. | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Cumberland Pharmaceuticals, Inc. | 2 | $29 |
| Janssen Scientific Affairs, LLC | 1 | $29 |
| La Jolla Pharmaceutical Company | 1 | $22 |
| Genentech USA, Inc. | 1 | $19 |
| Invivyd Inc | 1 | $14 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $12 |
| Nabriva Therapeutics, PLC | 1 | $11 |
| Dynavax Technologies Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,950,221 in reported general payments places this provider in the 95th percentile of 576 infectious disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 149 | $588,873 |
| TivicayDolutegravir Sodium | 60 | $164,551 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 41 | $162,165 |
| DovatoDolutegravir Sodium/Lamivudine | 54 | $158,747 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 25 | $151,053 |
| TrogarzoIbalizumab-Uiyk | 26 | $144,154 |
| CabenuvaCabotegravir/Rilpivirine | 17 | $115,418 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 24 | $107,878 |
| CresembaIsavuconazonium Sulfate | 17 | $100,069 |
| Daptomycin | 141 | $89,687 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 22 | $80,711 |
| PifeltroDoravirine | 26 | $45,063 |
| ErtapenemErtapenem Sodium | 83 | $35,049 |
| DescovyEmtricitabine/Tenofov Alafenam | 12 | $30,130 |
| Meropenem | 106 | $25,064 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $1,334,460 | $619,003161 claims |
| Viiv Healthcare CompanyTivicay, Triumeq, Dovato, Cabenuva | $732,887 | $600,881172 claims |
| Theratechnologies Inc.Trogarzo | $280,341 | $144,15426 claims |
| Janssen Products, LPSymtuza | $125 | $107,87824 claims |
| Astellas Pharma US IncCresemba | $483 | $100,06917 claims |
| MerckPifeltro, Isentress | $849 | $70,10637 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 576 infectious disease providers in Texas.
Other infectious disease in Dallas
- Mamta JainDallas$3.7M
- Elizabeth RaceDallas$1.5M
- David GreenbergDallas$1.2M
- Roger BedimoDallas$976K
- Theodoros KelesidisDallas$715K
- Uriel SandkovskyDallas$616K
- Jeremy ChowDallas$500K
- Satish MocherlaDallas$417K
- Edward DominguezDallas$178K
- Tawanda GumboDallas$172K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.